Reaction Details Report a problem with these data
Target
E3 ubiquitin-protein ligase Mdm2
Ligand
BDBM50448932
Substrate
n/a
Meas. Tech.
ChEMBL_1296786 (CHEMBL3132469)
IC50
1.3±n/a nM
Citation
Sun, D; Li, Z; Rew, Y; Gribble, M; Bartberger, MD; Beck, HP; Canon, J; Chen, A; Chen, X; Chow, D; Deignan, J; Duquette, J; Eksterowicz, J; Fisher, B; Fox, BM; Fu, J; Gonzalez, AZ; Gonzalez-Lopez De Turiso, F; Houze, JB; Huang, X; Jiang, M; Jin, L; Kayser, F; Liu, JJ; Lo, MC; Long, AM; Lucas, B; McGee, LR; McIntosh, J; Mihalic, J; Oliner, JD; Osgood, T; Peterson, ML; Roveto, P; Saiki, AY; Shaffer, P; Toteva, M; Wang, Y; Wang, YC; Wortman, S; Yakowec, P; Yan, X; Ye, Q; Yu, D; Yu, M; Zhao, X; Zhou, J; Zhu, J; Olson, SH; Medina, JC Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem 57:1454-72 (2014) [PubMed] Article
More Info.:
Target
Name:
E3 ubiquitin-protein ligase Mdm2
Synonyms:
Double minute 2 protein | Double minute 2 protein (HDM2) | E3 ubiquitin-protein ligase Mdm2 (p53-binding protein Mdm2) | Hdm2 | Human Double Minute 2 (HDM2) | MDM2 | MDM2-MDMX | MDM2_HUMAN | p53-Binding Protein MDM2 | p53-binding protein
Type:
Oncoprotein
Mol. Mass.:
55196.54
Organism:
Human
Description:
Q00987
Residue:
491
Sequence:
MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP